Singh Biotechnology, LLC. (SBT) is a biotech organization in the business of discovering and developing unique and proprietary therapeutic agents for the treatment of a variety of cancers and autoimmune diseases by leveraging a novel technology platform.
Using this technology platform SBT has been able to generate therapeutic agents that specifically target intracellular molecules of interest, which are mutated, hyper expressed, or play an important role in the pathogenesis of diseases.
Our proprietary technology and therapeutic agent's have enabled us to specifically target and inhibit:
Currently Singh Biotechnology, LLC. has a proprietary anti-mutated KRAS inhibitor and three anti-TNF-alpha inhibitors in preclinical studies. SBT’s lead therapeutic agent, anti-STAT3 inhibitor (SBT-100) is near completion of its preclinical studies.
Singh Biotechnology, LLC. has patented its novel therapeutic disease agents which are ‘small’ in size when compared to other traditional pharmaceutical compounds that target cell membrane receptors.
Science is a series of judgments, revised without ceasing.
- Pierre Emile Duclaux